Recruitment
Patients with primary biliary cholangitis or primary/secondary sclerosing cholangitis attending (outpatient) clinics of participating departments of gastroenterology and hepatology, who report an itch intensity of ≥ 5 out of 10.

Eligibility
Investigator assesses eligibility, obtains informed consent and collects baseline data:
VAS & 5D itch scores, LSDI2.0 questionnaire, blood withdrawal.

Exclusion
All patients that do not give informed consent and/or do not meet in- and exclusion criteria.

Day 0: Randomization
N=84

Day 1: Start of treatment
N=42
Bezafibrate 400mg tablet q.d. for 21 days
Patient diary

Day 1: Start of treatment
N=42
Identical placebo tablet q.d. for 21 days
Patient diary

Any drop-out will be substituted by inclusions of new study subjects

Day 21: End of treatment
VAS & 5D itch scores, LSDI2.0 questionnaire, blood withdrawal

Any drop-out will not be substituted

Day 35: Follow-up
VAS & 5D itch scores, LSDI2.0 questionnaire, blood withdrawal